Marc Cohen is a co-founder, Executive Chairman and CEO of NextRNA Therapeutics. He is a co-founder of C4 Therapeutics and has served as a member of the Board of Directors and as Executive Chairman since October 2015. Since December 2011, Marc has served as the Chairman and co-Chief Executive Officer of Bublup, Inc., an online knowledge-sharing and organization platform, and has served as co-Chief Executive Officer of Cobro Ventures, Inc., an investment management company for technology and biotechnology companies, since October 2013. Marc is also Chairman of Frequency Therapeutics, Inc., a regenerative medicine biotechnology company, and Executive Chairman of Mana Therapeutics, Inc., a cellular therapies biotechnology company focused on educating immune cells to target cancer, positions in which he has served since September 2016 and January 2018, respectively. He has also served as Executive Chairman of Regenacy Pharmaceuticals, Inc., a biotechnology company, focused on diabetic and other peripheral neuropathies, since January 2016, Executive Chairman of OncoPep, Inc., a cancer vaccine biotechnology company, since January 2010, and Executive Chairman of Raqia Therapeutics, Inc., a CAR-T cell therapies company for cancer and other diseases, since July 2020.
Marc is also the co-founder of the Dana-Farber Innovations Research Fund, a venture philanthropy fund focused on early stage research. He was co-founder and served as Chief Executive Officer and Chairman of OPNET Technologies, Inc., a software company that provided performance management tools for computer networks and applications, from 1986 through its acquisition in 2012.
Marc holds an M.S. in Electrical Engineering from Stanford University and an A.B. in Engineering Sciences from Harvard University.